Project Grant R33CA272339
Award Date
8/14/24
Completion Date
7/31/27
Dollars Obligated
$240K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
The National Cancer Institute (NCI), under CFDA 93.396 - Cancer Biology Research, awarded a $449,726 project grant to the University of Illinois to develop tools that enable the rapid analysis of changes in protein interactions within living cells. The project aims to significantly improve the sensitivity and temporal resolution of existing proximity labeling approaches used to map dynamic protein interactomes. Key innovations include engineering biotin ligases that can label proteins with...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $2,186,372 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of California, Irvine (UCI) to support a 5-year research program investigating "tipping points" in cancer initiation and progression. The program will leverage mouse models to study stochastic, non-genetic cellular transitions and cell-cell interactions that drive the progression from pre-malignant to...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
The National Cancer Institute (NCI) awarded a $238,722 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, awarded on August 18, 2025, will fund research to investigate the role of mutagenic DNA repair mechanisms, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. The research aims to define the specific mechanisms by which...
The National Cancer Institute (NCI) awarded a $516,648 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Rockefeller University. The grant, effective September 18, 2024 through March 31, 2027, supports research to discover and characterize covalent ligands for the oncoprotein CIP2A, which is a unique therapeutic vulnerability in BRCA1/2-deficient cancers. The project aims to: (1) identify potent and selective covalent ligands for CIP2A, (2) develop heterobifunctional...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Sloan-Kettering Institute for Cancer Research. The 5-year grant, effective June 5, 2025, will fund research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance in cancer. The key products of this research will be a better understanding of DNA damage repair pathways and how they contribute...
The National Cancer Institute (NCI) awarded a $254,638 project grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Pennsylvania. The grant supports the design, synthesis, and biological characterization of macrocyclic collagen mimetic peptides (CMPs) targeted against the cancer-implicated DDR2 kinase. The goal is to develop biochemical tools for modulating the collagen interactome, with a focus on the collagen-DDR2 interaction, which plays a key role in cancer...
The National Cancer Institute awarded a $423,078 Project Grant (CFDA Program 93.394 - Cancer Detection and Diagnosis Research) to the California Institute of Technology (Caltech) to develop a machine learning framework that uses spatial proteomic data to identify signaling molecules and guidance cues that can promote T-cell infiltration and function in "cold" tumors. The project aims to generalize this approach across a broader range of cancer types and larger patient data sets, and...